ImmunoCellular Therapeutics Enters into Option Agreement with The University of Texas M. D. Anderson Cancer Center for a Novel Cancer Stem Cell Therapy
December 02, 2009 08:00 AM Eastern Time
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson...
It is rare when antidiscrimination law is extended to a whole new group of people, but that happened on Saturday, when a federal ban on discriminating on the basis of genetic background took effect. The new law is an important step in protecting people who have inherited a predisposition to disease. It removes a significant obstacle to genetic testing, which can help prevent and treat serious illnesses.
ScienceDaily (Nov. 12, 2009) — Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in the November 12 issue of Nature, lays the foundation for a new kind of therapy aimed directly at a critical human protein -- one of a few thousand so-called transcription factors -- that could someday be used to treat a variety of diseases, especially multiple...
MADRID, Nov 2 (Reuters) - Spanish biotechnology firm Zeltia (ZEL.MC) won final European approval on Monday for its Yondelis drug to treat ovarian cancer, sending its shares higher. The authorisation from the European Commission, clearing the product for sale, had been expected after it was recommended for approval by the European Medicines Agency in September.
The sale of Yondelis for ovarian cancer will begin in Britain, Germany, Austria, Denmark,...
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.
The patent, entitled "Vitamin Receptor Binding Drug Delivery Conjugates" (U.S. Patent No. 7,601,332), covers novel conjugation...
